Geneos Wealth Management’s T. Rowe Price Capital Appreciation Equity ETF TCAF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$256K Buy
6,062
+1,124
+23% +$47.4K ﹤0.01% 995
2026
Q2
$203K Buy
4,938
+1,783
+57% +$70.5K ﹤0.01% 987
2026
Q1
$112K Buy
3,155
+850
+37% +$31.8K ﹤0.01% 1138
2025
Q4
$88.1K Buy
2,305
+310
+16% +$11.9K ﹤0.01% 1186
2025
Q3
$75.2K Buy
1,995
+400
+25% +$14.6K ﹤0.01% 1221
2025
Q2
$56.3K Buy
1,595
+1,130
+243% +$37.1K ﹤0.01% 1506
2025
Q1
$15K Buy
+465
New +$15.6K ﹤0.01% 2076

Other funds holding TCAF

Geneos Wealth Management's TCAF Position: Q3 2026 in Review

Geneos Wealth Management increased its T. Rowe Price Capital Appreciation Equity ETF (TCAF) stake by 23% in Q3 2026, buying an estimated $47.4K and bringing the position to 6,062 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Geneos Wealth Management first reported a position in TCAF in Q1 2025 and has held it in 7 quarters since. 369 funds tracked by Wall St. Rank hold TCAF as of Q3 2026.

  • Geneos Wealth Management held 6,062 shares of T. Rowe Price Capital Appreciation Equity ETF worth $256K as of Q3 2026.
  • Geneos Wealth Management bought 1,124 T. Rowe Price Capital Appreciation Equity ETF shares in Q3 2026, an estimated $47.4K.
  • T. Rowe Price Capital Appreciation Equity ETF made up ﹤0.01% of Geneos Wealth Management's portfolio in Q3 2026, its #995 holding.
  • Geneos Wealth Management first reported a position in T. Rowe Price Capital Appreciation Equity ETF in Q1 2025 and has held it in 7 quarters since.
  • 369 funds tracked by Wall St. Rank held T. Rowe Price Capital Appreciation Equity ETF as of Q3 2026.

Based on Geneos Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.